Investigating the Rational Use of Lipid-Lowering Drugs in Azar Cohort Population

Abstract

Hyperlipidemia is a metabolic disorder characterized by either an increased synthesis or a diminished breakdown of lipoproteins that facilitate the transport of cholesterol and triglycerides in the bloodstream. Modifications to dyslipidemia can be achieved through dietary changes and pharmacological interventions that influence lipid metabolism via various mechanisms. To enhance treatment efficacy, minimize drug side effects, reduce healthcare costs, and foster improved collaboration between medical professionals and patients throughout the treatment process, it is crucial to investigate the rational use of lipid-lowering drugs.Objective: The objective of this study is to determine the rational use of lipid-lowering drugs in Azar cohort population.Methods: In this cross-sectional study, we used the collected data of the Azar cohort study. Based on the objectives of the study, 1271 subjects were included. the data collected from the Azar cohort study approved by liver and Gastrointestinal Diseases Research center. In this study, demographic information, drug information and clinical tests collected by the questionnaire. Then, the rational use of lipid lowering drugs was evaluated according to the AHA/ACC and CCS [2021] treatment guidelines.Results: In this study, a total of 1271 users of lipid-lowering drugs were studied. Of 1271 subjects, 779 patients (61.29%) used their drugs irrationally. Among the study subjects, the most prevalent disease was cardiovascular disease. Moreover, the most commonly prescribed medication was Atorvastatin 20 mg (62.07%).Conclusions: According to our findings, the majority number of our subjects use lipid lowering medications irrationally. Furthermore, the prevalence of irrational use was notably higher among women than men. 37.6% of the people participating in the study were women with irrational consumption, 23.69% were men with irrational consumption, 22.82% were women with rational consumption and 15.89% were men with rational consumption of lipid-lowering drugs.